The efficacy of andrographolide and its combination with betulinic acid in the treatment of triple-negative breast cancer

Daniel Weber, Mixia Zhang, Pengwei Zhuang, Yanjun Zhang, Janelle Wheat, Geoffrey Currie

Research output: Contribution to journalArticle

21 Downloads (Pure)

Abstract

Purpose: Breast Cancer is the most prevalent form of cancer in women around the world. Breast cancers that do not express the genes for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2) are referred to as triple-negative breast cancers (TNBC). TNBC has a relatively poorer prognosis than the major breast cancer sub-types with conventional chemotherapy eventually failing due to acquired drug resistance, toxic side effects and the presence of a deregulated immune response. Hence, there is an urgent need for new treatment approaches. New treatments for overcoming these drawbacks include the use of plant extracts.
Study design: In this study, we investigated the efficacy and the underlying molecular mechanism(s) of Andrographolide (Andro), a naturally abundant phytochemical against TNBC MDA-MB-231 and MDA-MB-468cell lines. The efficacy of the combination of Andro with Betulinic Acid (BetA) was also determined.
Results: Here we report that Andro was able to inhibit the inflammatory response, inhibit angiogenesis and cause cell cycle arrest ultimately causing apoptosis in TNBC cells. Our findings support that the identification of naturally occurring
anti-tumour compounds may provide a chemotherapeutic approach for the treatment of TNBC.
Conclusion: Overall, our results provide a molecular basis for the ability of Andro and BetAto mediate apoptosis, suppress inflammation and inhibit angiogenesis in TNBC cell lines.
Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalCancer Therapy & Oncology International Journal
Volume4
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'The efficacy of andrographolide and its combination with betulinic acid in the treatment of triple-negative breast cancer'. Together they form a unique fingerprint.

Cite this